Ann Rehabil Med > Volume 42(6); 2018 > Article |
|
Variable | Ho group (n=14) | Ve group (n=14) | p-value |
---|---|---|---|
Sex (male:female) | 4:10 | 3:11 | 1.00 |
Age (yr) | 55.1±11.2 | 53.7±12.1 | 0.76 |
Height (cm) | 162.1±6.7 | 160.1±6.9 | 0.46 |
Weight (kg) | 56.1±9.3 | 56.6±7.0 | 0.86 |
Outcome measure | Group | t0 | t1 | t2 | t3 |
The change by time |
Between group difference for the change by time (p-value) | t0 vs t1 | t0 vs t2 | t0 vs t3 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Ho | Ve | ||||||||||
VAS | Ho | 4.3±1.5 | 3.2±1.1 | 2.0±0.9 | 2.6±1.0 | <0.001 | <0.001 | 0.929 | 0.059 | 0.001* | 0.040* |
Ve | 4.9±1.9 | 3.6±1.6 | 2.8±1.3 | 3.1±1.5 | 0.135 | 0.002* | 0.005* | ||||
ODI | Ho | 21.57±4.11 | 18.07±3.50 | 14.57±3.67 | 14.71±5.47 | <0.001 | <0.001 | 0.595 | 0.003* | 0.000* | 0.000* |
Ve | 22.36±6.76 | 18.86±5.04 | 16.21±4.02 | 17.43±5.42 | 0.158 | 0.011* | 0.003* | ||||
Muscle strength | |||||||||||
LFPT (N·m) | Ho | 109.05±46.67 | 124.44±48.87 | 150.24±32.54 | 140.98±38.74 | <0.001 | <0.001 | 0.619 | 0.758 | 0.001* | 0.012* |
Ve | 92.51±30.23 | 124.26±32.87 | 144.54±38.06 | 131.74±22.30 | 0.003* | 0.001* | 0.001* | ||||
LEPT (N·m) | Ho | 112.89±52.45 | 147.91±54.60 | 197.34±63.79 | 182.64±54.32 | <0.001 | <0.001 | 0.742 | 0.069 | 0.000* | 0.001* |
Ve | 113.04±82.72 | 148.91±57.60 | 186.36±70.61 | 181.63±52.69 | 0.002* | 0.000* | 0.000* | ||||
LFAP (W) | Ho | 12.67±9.55 | 24.26±20.76 | 41.78±24.80 | 33.11±23.50 | <0.001 | <0.001 | 0.363 | 0.062 | 0.000* | 0.005* |
Ve | 10.32±7.30 | 24.30±17.48 | 32.62±22.48 | 29.89±17.97 | 0.017* | 0.007* | 0.003* | ||||
LEAP (W) | Ho | 10.58±6.99 | 20.16±14.56 | 40.38±24.79 | 39.59±27.26 | <0.001 | <0.001 | 0.878 | 0.067 | 0.002* | 0.003* |
Ve | 10.43±8.97 | 23.01±18.78 | 40.86±23.00 | 40.74±23.09 | 0.029* | 0.002* | 0.001* | ||||
Muscle thickness | |||||||||||
TrA (mm) | Ho | 2.93±0.67 | 2.94±0.61 | 3.11±0.57 | 3.10±0.84 | 0.153 | 0.561 | 0.568 | 1.000 | 0.199 | 0.530 |
Ve | 2.86±0.44 | 2.88±0.36 | 2.97±0.40 | 2.86±0.40 | 1.000 | 1.000 | 1.000 | ||||
Multi (mm) | Ho | 23.29±4.25 | 23.67±3.91 | 23.73±3.33 | 23.37±2.52 | 0.737 | 0.380 | 0.906 | 1.000 | 1.000 | 1.000 |
Ve | 22.83±2.57 | 23.05±2.17 | 23,48±2.13 | 22.84±2.57 | 1.000 | 1.000 | 1.000 | ||||
Balance control | |||||||||||
AP | Ho | 3.86±1.23 | 2.96±0.65 | 2.38±0.71 | 2.50±0.67 | <0.001 | <0.001 | 0.647 | 0.017* | 0.000* | 0.001* |
Ve | 4.00±0.80 | 3.11±0.89 | 2.52±0.71 | 2.41±0.65 | 0.000* | 0.000* | 0.000* | ||||
ML | Ho | 3.83±1.26 | 2.58±0.97 | 2.23±0.79 | 2.28±0.71 | <0.001 | <0.001 | 0.522 | 0.104 | 0.005* | 0.014* |
Ve | 3.89±1.79 | 3.02±1,27 | 2.25±0.79 | 2.19±0.71 | 0.008* | 0.001* | 0.010* |
Values are presented as mean±standard deviation.
HVE, horizontal vibration exercise; VVE, vertical vibration exercise; Ho, horizontal vibration group; Ve, vertical vibration group; t0, assessment at baseline; t1, assessment at 6 weeks; t2, assessment at 12 weeks; t3, assessment performed after 4 weeks from the end of intervention; VAS, visual analogue scale; ODI, Oswestry disability index; LFPT, lumbar flexor peak torque; LEPT, lumbar extensor peak torque; LFAP, lumbar flexor average power; LEAP, lumbar extensor average power; TrA, transverse abdominis; Multi, multifidus; AP, anterior-posterior; ML, medial-lateral.
The Clinical Effect of Facet Joint Injection in Chronic Low Back Pain Patients1996 March;20(1)